Summary
This review examines antimicrobial peptides and nanotechnology as emerging therapeutic strategies to address gram-negative bacterial infections resistant to conventional antibiotics. The authors synthesise current evidence on mechanistic pathways by which these approaches overcome established resistance mechanisms, with implications for clinical development. The work contributes to literature on alternative antimicrobial modalities in response to the antibiotic resistance crisis.
Regional applicability
Findings are relevant to UK clinical practice and antimicrobial stewardship policy, particularly as antibiotic resistance in gram-negative pathogens (such as Pseudomonas aeruginosa and Acinetobacter baumannii) represents a significant healthcare burden. However, clinical translation and NHS adoption would require further evidence from controlled trials and regulatory approval.
Key measures
Mechanisms of action of antimicrobial peptides and nanoparticles; bacterial resistance circumvention pathways; comparative efficacy against gram-negative pathogens
Outcomes reported
The review synthesises evidence on antimicrobial peptides (AMPs) and nanotechnological approaches as alternative strategies to combat gram-negative bacterial infections resistant to conventional antibiotics. The study examined mechanistic pathways by which these modalities circumvent bacterial resistance mechanisms and their comparative efficacy.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.